ArticleJournal of managed care & specialty pharmacy2024

The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B.

Jyotirmoy Sarker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.